Tirzepatide is a dual-agonist it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide)
Compounded products are not FDA-approved and have not been evaluated by the FDA for safety or efficacy
And I started thinking that there was a pattern there that needed to be investigated. You found a 1.5% increase in hypotension in patients six months after starting GLP-1s
Retatrutide is not yet FDA-approved , and thus remains officially an investigational therapy
instead, they may improve cerebral blood flow (increased blood to the brain), support neuron metabolism, or protect brain cells from oxidative stress
This review synthesizes the cellular and physiological mechanisms, contrasts incretin-based therapies with lipid-lowering pharmacotherapy, summarizes the principal randomized trials, evaluates the distinction between plaque regression and plaque stabilization, and outlines unresolved questions and clinical-implementation considerations